How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?

Amit K. Verma, J. Pedicano, S. Trifilio, S. Singhal, M. Tallman, J. Winter, S. Williams, L. Gordon, J. Monreal, J. Mehta

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Growth factors are routinely used after autotransplantation to accelerate hematopoietic recovery, and are continued until the absolute neutrophil count (ANC) is ≥0.5 × 109/l on 3 consecutive days. Since ANC often increases to very high levels with this strategy, we discontinued growth factor on the first day ANC reached 0.5 × 109/l in 45 patients (Study Group), and compared their subsequent ANC to 108 historic controls who received growth factor longer. While ANC on the day after reaching 0.5 × 109/l was comparable between groups, ANC on the third day was significantly higher in the Control Group (2.3 vs 4.9 × 109/l; P = 0.0003). When compared to the first day, ANC in the Study Group was higher by a median of 140% on the third day and by 450% in the Control Group (P = 0.0002). A significantly higher proportion of patients experienced a decline in ANC after the first day in the Study Group. However, only one patient in the Study Group became neutropenic transiently and ANC recovered spontaneously the next day. The incidence of fever and hospitalization were comparable. We conclude that growth factors can be discontinued after autotransplantation the day the ANC reaches 0.5 × 109/l, without compromising neutrophil recovery.

Original languageEnglish (US)
Pages (from-to)715-719
Number of pages5
JournalBone Marrow Transplantation
Volume33
Issue number7
DOIs
StatePublished - Apr 2004
Externally publishedYes

Fingerprint

Hematopoietic Stem Cells
Intercellular Signaling Peptides and Proteins
Neutrophils
Transplants
Autologous Transplantation
Transplant Recipients
Control Groups
Hospitalization
Fever

Keywords

  • Autologous hematopoietic stem cell transplantation
  • Engraftment
  • Filgrastim
  • Neutropenia
  • Sargramostim

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? / Verma, Amit K.; Pedicano, J.; Trifilio, S.; Singhal, S.; Tallman, M.; Winter, J.; Williams, S.; Gordon, L.; Monreal, J.; Mehta, J.

In: Bone Marrow Transplantation, Vol. 33, No. 7, 04.2004, p. 715-719.

Research output: Contribution to journalArticle

Verma, AK, Pedicano, J, Trifilio, S, Singhal, S, Tallman, M, Winter, J, Williams, S, Gordon, L, Monreal, J & Mehta, J 2004, 'How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?', Bone Marrow Transplantation, vol. 33, no. 7, pp. 715-719. https://doi.org/10.1038/sj.bmt.1704415
Verma, Amit K. ; Pedicano, J. ; Trifilio, S. ; Singhal, S. ; Tallman, M. ; Winter, J. ; Williams, S. ; Gordon, L. ; Monreal, J. ; Mehta, J. / How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?. In: Bone Marrow Transplantation. 2004 ; Vol. 33, No. 7. pp. 715-719.
@article{33d78832aec64de8aa17f04166bdc3ff,
title = "How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?",
abstract = "Growth factors are routinely used after autotransplantation to accelerate hematopoietic recovery, and are continued until the absolute neutrophil count (ANC) is ≥0.5 × 109/l on 3 consecutive days. Since ANC often increases to very high levels with this strategy, we discontinued growth factor on the first day ANC reached 0.5 × 109/l in 45 patients (Study Group), and compared their subsequent ANC to 108 historic controls who received growth factor longer. While ANC on the day after reaching 0.5 × 109/l was comparable between groups, ANC on the third day was significantly higher in the Control Group (2.3 vs 4.9 × 109/l; P = 0.0003). When compared to the first day, ANC in the Study Group was higher by a median of 140{\%} on the third day and by 450{\%} in the Control Group (P = 0.0002). A significantly higher proportion of patients experienced a decline in ANC after the first day in the Study Group. However, only one patient in the Study Group became neutropenic transiently and ANC recovered spontaneously the next day. The incidence of fever and hospitalization were comparable. We conclude that growth factors can be discontinued after autotransplantation the day the ANC reaches 0.5 × 109/l, without compromising neutrophil recovery.",
keywords = "Autologous hematopoietic stem cell transplantation, Engraftment, Filgrastim, Neutropenia, Sargramostim",
author = "Verma, {Amit K.} and J. Pedicano and S. Trifilio and S. Singhal and M. Tallman and J. Winter and S. Williams and L. Gordon and J. Monreal and J. Mehta",
year = "2004",
month = "4",
doi = "10.1038/sj.bmt.1704415",
language = "English (US)",
volume = "33",
pages = "715--719",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?

AU - Verma, Amit K.

AU - Pedicano, J.

AU - Trifilio, S.

AU - Singhal, S.

AU - Tallman, M.

AU - Winter, J.

AU - Williams, S.

AU - Gordon, L.

AU - Monreal, J.

AU - Mehta, J.

PY - 2004/4

Y1 - 2004/4

N2 - Growth factors are routinely used after autotransplantation to accelerate hematopoietic recovery, and are continued until the absolute neutrophil count (ANC) is ≥0.5 × 109/l on 3 consecutive days. Since ANC often increases to very high levels with this strategy, we discontinued growth factor on the first day ANC reached 0.5 × 109/l in 45 patients (Study Group), and compared their subsequent ANC to 108 historic controls who received growth factor longer. While ANC on the day after reaching 0.5 × 109/l was comparable between groups, ANC on the third day was significantly higher in the Control Group (2.3 vs 4.9 × 109/l; P = 0.0003). When compared to the first day, ANC in the Study Group was higher by a median of 140% on the third day and by 450% in the Control Group (P = 0.0002). A significantly higher proportion of patients experienced a decline in ANC after the first day in the Study Group. However, only one patient in the Study Group became neutropenic transiently and ANC recovered spontaneously the next day. The incidence of fever and hospitalization were comparable. We conclude that growth factors can be discontinued after autotransplantation the day the ANC reaches 0.5 × 109/l, without compromising neutrophil recovery.

AB - Growth factors are routinely used after autotransplantation to accelerate hematopoietic recovery, and are continued until the absolute neutrophil count (ANC) is ≥0.5 × 109/l on 3 consecutive days. Since ANC often increases to very high levels with this strategy, we discontinued growth factor on the first day ANC reached 0.5 × 109/l in 45 patients (Study Group), and compared their subsequent ANC to 108 historic controls who received growth factor longer. While ANC on the day after reaching 0.5 × 109/l was comparable between groups, ANC on the third day was significantly higher in the Control Group (2.3 vs 4.9 × 109/l; P = 0.0003). When compared to the first day, ANC in the Study Group was higher by a median of 140% on the third day and by 450% in the Control Group (P = 0.0002). A significantly higher proportion of patients experienced a decline in ANC after the first day in the Study Group. However, only one patient in the Study Group became neutropenic transiently and ANC recovered spontaneously the next day. The incidence of fever and hospitalization were comparable. We conclude that growth factors can be discontinued after autotransplantation the day the ANC reaches 0.5 × 109/l, without compromising neutrophil recovery.

KW - Autologous hematopoietic stem cell transplantation

KW - Engraftment

KW - Filgrastim

KW - Neutropenia

KW - Sargramostim

UR - http://www.scopus.com/inward/record.url?scp=4644227910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644227910&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704415

DO - 10.1038/sj.bmt.1704415

M3 - Article

C2 - 14743195

AN - SCOPUS:4644227910

VL - 33

SP - 715

EP - 719

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -